Weintraub WS., COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007 Apr 12;356(15):1503-16. \[[PubMed: 17387127](https://pubmed.ncbi.nlm.nih.gov/17387127)\] 8. Rayner-Hartley E, Sedlak T. Ranolazine: A Contemporary Review. J Am Heart Assoc. 2016 Mar 15;5(3):e003196. \[[PMC free article: PMC4943285](/pmc/articles/PMC4943285/)\] \[[PubMed: 26979079](https://pubmed.ncbi.nlm.nih.gov/26979079)\] 9. Silva FM, Pesaro AE, Franken M, Wajngarten M. Acute management of unstable angina and non-ST segment elevation myocardial infarction. Einstein (Sao Paulo). 2015 Jul-Sep;13(3):454-61. \[[PMC free article: PMC4943796](/pmc/articles/PMC4943796/)\] \[[PubMed: 26466065](https://pubmed.ncbi.nlm.nih.gov/26466065)\] 10. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK., Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001 Aug 16;345(7):494-502. \[[PubMed: 11519503](https://pubmed.ncbi.nlm.nih.gov/11519503)\] 11. Hjemdahl P, Eriksson SV, Held C, Forslund L, Näsman P, Rehnqvist N. Favourable long term prognosis in stable angina pectoris: an extended follow up of the angina prognosis study in Stockholm (APSIS). Heart. 2006 Feb;92(2):177-82. \[[PMC free article: PMC1860751](/pmc/articles/PMC1860751/)\] \[[PubMed: 15951393](https://pubmed.ncbi.nlm.nih.gov/15951393)\] 12. Hemingway H, McCallum A, Shipley M, Manderbacka K, Martikainen P, Keskimäki I. Incidence and prognostic implications of stable angina pectoris among women and men. JAMA. 2006 Mar 22;295(12):1404-11. \[[PubMed: 16551712](https://pubmed.ncbi.nlm.nih.gov/16551712)\] 13. Kloner RA, Chaitman B. Angina and Its Management. J Cardiovasc Pharmacol Ther. 2017 May;22(3):199-209. \[[PubMed: 28196437](https://pubmed.ncbi.nlm.nih.gov/28196437)\] **Disclosure:** Christine Hermiz declares no relevant financial relationships with ineligible companies. **Disclosure:** Yub Raj Sedhai declares no relevant financial relationships with ineligible companies.